BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ionis Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ionis Pharmaceuticals's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07511361-531@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tonlamarsen: Phase 2 readout est. (NCT07511361)
DESCRIPTION:Tonlamarsen\, phase 2\, Hypertension.\nStudy: Study of Efficacy
  and Safety of Tonlamarsen in Participants With a Recent Hospitalization a
 nd a Concurrent Episode of Acute Severe Hypertension\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tonlamarsen#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07511361
URL:https://assetmemo.bio/drug/tonlamarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05392114-10797@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dawnzera (Donidalorsen): Phase 3 readout est. (NCT05392114)
DESCRIPTION:Dawnzera (Donidalorsen)\, phase 3\, Hereditary Angioedema.\nStu
 dy: A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in
  the Prophylactic Treatment of Hereditary Angioedema (HAE)\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/donidalorsen#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05392114
URL:https://assetmemo.bio/drug/donidalorsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019922-8868@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elsunersen: Phase 3 readout est. (NCT07019922)
DESCRIPTION:Elsunersen\, phase 3\, Epilepsy.\nStudy: A Clinical Trial of El
 sunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety\nEstimated p
 rimary completion: December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/elsunersen#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07019922
URL:https://assetmemo.bio/drug/elsunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681351-1044@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05681351)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutan
 eously to Participants With Severe Hypertriglyceridemia (SHTG)\nEstimated 
 primary completion: March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olezarsen#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05681351
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05185843-1044@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05185843)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) A
 dministered to Adults With Familial Chylomicronemia Syndrome (FCS) Previou
 sly Treated With Volanesorsen\nEstimated primary completion: June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/olezarsen#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05185843
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914609-10803@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Obudanersen: Phase 3 readout est. (NCT06914609)
DESCRIPTION:Obudanersen\, phase 3\, Angelman Syndrome.\nStudy: REVEAL: A Ph
 ase 3 Study of Obudanersen (ION582) in Angelman Syndrome\nEstimated primar
 y completion: August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/obudanersen#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06914609
URL:https://assetmemo.bio/drug/obudanersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04856982-10800@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270807
DTEND;VALUE=DATE:20270808
SUMMARY:Qalsody (Tofersen): Phase 3 readout est. (NCT04856982)
DESCRIPTION:Qalsody (Tofersen)\, phase 3\, Amyotrophic Lateral Sclerosis.\n
 Study: Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and Abo
 ut Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Develop
 ed ALS Symptoms\nEstimated primary completion: 7 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tofersen#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04856982
URL:https://assetmemo.bio/drug/tofersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604974-1085@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:ION775: Phase 2 readout est. (NCT07604974)
DESCRIPTION:ION775\, phase 2\, Severe Hypertriglyceridemia.\nStudy: A Study
  to Assess the Safety\, Tolerability and Efficacy of ION775\nEstimated pri
 mary completion: September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ion775#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07604974
URL:https://assetmemo.bio/drug/ion775#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067790-10799@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Spinraza (Nusinersen): Phase 3 readout est. (NCT05067790)
DESCRIPTION:Spinraza (Nusinersen)\, phase 3\, Spinal Muscular Atrophy.\nStu
 dy: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB0
 58) Given as Injections to Participants With Spinal Muscular Atrophy (SMA)
  Who Were Previously Treated With Risdiplam (ASCEND)\nEstimated primary co
 mpletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nusinersen#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05067790
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05130450-1044@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05130450)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) i
 n Participants With Familial Chylomicronemia Syndrome (FCS)\nEstimated pri
 mary completion: February 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olezarsen#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05130450
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813911-1038@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT06813911)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclis
 iran in Participants With Elevated Lp(a) and Established ASCVD\nEstimated 
 primary completion: 3 February 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06813911
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782827-10803@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Obudanersen: Phase 3 readout est. (NCT07782827)
DESCRIPTION:Obudanersen\, phase 3\, Angelman Syndrome.\nStudy: CHAMPION: A 
 Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Child
 ren and Adults With Angelman Syndrome (AS)\nEstimated primary completion: 
 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obudanersen
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 82827
URL:https://assetmemo.bio/drug/obudanersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797610-5037@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20280525
DTEND;VALUE=DATE:20280526
SUMMARY:Sefaxersen: Phase 3 readout est. (NCT05797610)
DESCRIPTION:Sefaxersen\, phase 3\, IgA Nephropathy.\nStudy: A Study to Eval
 uate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants Wit
 h Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression\n
 Estimated primary completion: 25 May 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sefaxersen#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05797610
URL:https://assetmemo.bio/drug/sefaxersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298447-10797@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Dawnzera (Donidalorsen): Phase 3 readout est. (NCT07298447)
DESCRIPTION:Dawnzera (Donidalorsen)\, phase 3\, Hereditary Angioedema.\nStu
 dy: Donidalorsen Treatment in Children With Hereditary Angioedema\nEstimat
 ed primary completion: June 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/donidalorsen#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07298447
URL:https://assetmemo.bio/drug/donidalorsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05071300-10798@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Wainua (Eplontersen): Phase 3 readout est. (NCT05071300)
DESCRIPTION:Wainua (Eplontersen)\, phase 3.\nStudy: A Study to Assess the L
 ong-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884\
 , IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyret
 in-Mediated Amyloid Polyneuropathy\nEstimated primary completion: August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/eplontersen#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05071300
URL:https://assetmemo.bio/drug/eplontersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05667493-10798@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Wainua (Eplontersen): Phase 3 readout est. (NCT05667493)
DESCRIPTION:Wainua (Eplontersen)\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: An Extension Study to Assess Long-Term Safety of 
 Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (
 ATTR-CM)\nEstimated primary completion: August 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/eplontersen#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05667493
URL:https://assetmemo.bio/drug/eplontersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07517263-1038@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20300109
DTEND;VALUE=DATE:20300110
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT07517263)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: An Open Label Extension (OLE) Study (Following Completion of CTQJ2
 30A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ
 230)\nEstimated primary completion: 9 January 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07517263
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05646381-1038@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20300312
DTEND;VALUE=DATE:20300313
SUMMARY:Pelacarsen: Phase 2 readout est. (NCT05646381)
DESCRIPTION:Pelacarsen\, phase 2\, Atherosclerotic Cardiovascular Disease.\
 nStudy: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowerin
 g With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Ste
 nosis\nEstimated primary completion: 12 March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05646381
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727538-1044@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT07727538)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen for the Treatment of Familial Chylomicr
 onemia Syndrome (FCS) in Pediatric Participants\nEstimated primary complet
 ion: August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ole
 zarsen#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07727538
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07531745-9008@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:ION337: Phase 1/2 readout est. (NCT07531745)
DESCRIPTION:ION337\, phase 1/2\, Epilepsy.\nStudy: ASCEND: Safety and Toler
 ability of ION337 for the Treatment of Dravet Syndrome\nEstimated primary 
 completion: December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ion337#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07531745
URL:https://assetmemo.bio/drug/ion337#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06875973-1038@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20301208
DTEND;VALUE=DATE:20301209
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT06875973)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Pelacarsen Roll-over Extension Program\nEstimated primary completi
 on: 8 December 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pelacarsen#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06875973
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05127226-10803@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Obudanersen: Phase 1/2 readout est. (NCT05127226)
DESCRIPTION:Obudanersen\, phase 1/2\, Angelman Syndrome.\nStudy: HALOS: A S
 afety\, Tolerability\, Pharmacokinetics and Pharmacodynamics Study of Mult
 iple Ascending Doses of ION582 in Participants With Angelman Syndrome\nEst
 imated primary completion: March 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/obudanersen#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05127226
URL:https://assetmemo.bio/drug/obudanersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
